Cancer

The Research Was Wrong: Study Shows Moderate Drinking Won’t Lengthen Your Life

PISCATAWAY, NJ / ACCESSWIRE / July 25, 2024 / Probably everyone has heard some variation of the conventional wisdom that…

2 years ago

Doug Cassidy Appointed President of the Deep 6 AI Precision Research Ecosystem, the Largest Network of Sites and Sponsors Using AI To Accelerate Research

PASADENA, Calif., July 24, 2024 /PRNewswire/ -- Deep 6 AI, the leader in AI-powered patient recruitment and real-world data (RWD), announced…

2 years ago

AI for Good: Insilico Medicine Hosts IMGAIA Product Launch Event

Announcing Sustainability Benchmarking Initiative and New Gen-AI Features of Pharma.AI Platform CAMBRIDGE, Mass., July 24, 2024 /PRNewswire/ -- Insilico Medicine…

2 years ago

Credit Unions Raise Over $1.5 Million To Help Move Kids Out of Hospitals and Onto Playgrounds

In a powerful display of unity, First Tech joined forces with fellow credit unions and industry partners to support children's…

2 years ago

AIM Announces New Positive Data on Ampligen’s Anti-Tumor Potential When Used as Part of a Combination Therapy

OCALA, Fla., July 24, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the…

2 years ago

ImPact Biotech Receives a €13.5M Investment Commitment from the European Innovation Council’s Accelerator Program

TEL AVIV, Israel, July 24, 2024 (GLOBE NEWSWIRE) -- ImPact Biotech, a clinical-stage biotechnology company focused on developing Padeliporfin vascular…

2 years ago

Autonomix Completes Licensing Transaction for FDA-Cleared Ablation Technology

RF Innovations’ Apex 6 Generator aligns with specifications required for Autonomix’s ablation system and facilitates ongoing development Transaction further reinforces…

2 years ago

Notable Labs Receives FDA Clearance to Proceed Further with Volasertib Phase 2 Study

Phase 2 dosing plan, agreed with FDA, paves the way to initiate patient enrollmentFOSTER CITY, Calif., July 24, 2024 (GLOBE…

2 years ago

Merus Announces First Patient Dosed in LiGeR-HN2, a Phase 3 Trial Evaluating Petosemtamab in 2/3L r/m HNSCC

Petosemtamab 1500 mg Q2W confirmed for both 2/3L phase 3 trial (LiGeR-HN2) and 1L trial (LiGeR-HN1) in r/m HNSCC following…

2 years ago